Simultaneous processing is one of the benefits of the expedited process in the UK. Your notion that they are “behind” is actually nonsense. And yes, NICE noted about 6 months ago or so that they were restarting their review.
As for what was discussed, NICE is all about access and pricing. Yes, it is scheduling and process, but it’s all about pricing and providing the drug to patients. Your suggestion that it isn’t is a nice way to further pretend this is going slow, but that is just not the case.
News 
Market Data 
Discover 
